Get the Stockscreener App
0.2426
0.66%
0.0016
After Hours:
.25
0.0074
+3.05%
Theriva Biologics Inc stock is traded at $0.2426, with a volume of 2.88M.
It is up +0.66% in the last 24 hours and up +7.58% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.241
Open:
$0.2336
24h Volume:
2.88M
Relative Volume:
0.16
Market Cap:
$8.19M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.2091
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
+23.78%
1M Performance:
+7.58%
6M Performance:
-45.24%
1Y Performance:
-85.98%
1-Day Range:
$0.23
$0.2523
1-Week Range:
$0.1868
$0.2603
52-Week Range:
$0.1651
$2.03
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2426 | 8.13M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theriva Biologics Inc Stock (TOVX) Latest News
How Theriva Biologics Inc. stock benefits from strong dollar2026 world cup usa national team group stage playmakers possession football winner prediction insights - Улправда
Theriva Biologics Incto Schedule End-of-Ph - 富途牛牛
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Yahoo Finance
Theriva Biologics gains EMA backing for VCN-01 phase 3 - MSN
Theriva receives EMA guidance for pancreatic cancer drug trial design By Investing.com - Investing.com Nigeria
Why Is Theriva Biologics Stock Gaining Monday? - Benzinga
Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Canada
Theriva Biologics (TOVX) Prepares for Phase 3 Trial with EMA Gui - GuruFocus
Theriva Biologics Announces EMA Advice on Phase 3 Trial for VCN-01 - TradingView — Track All Markets
Theriva Biologics (TOVX) outlines EMA CHMP advice on VCN-01 Phase 3 trial in metastatic pancreatic cancer - Stock Titan
EMA advice moves Theriva's VCN-01 toward Phase 3 pancreatic trial - Stock Titan
Guidance Update: What market sentiment indicators show for Theriva Biologics Inc. (SFY0) stock2025 Macro Impact & Growth Focused Entry Point Reports - moha.gov.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why - Defense World
What drives Theriva Biologics Inc stock priceDebt-to-Equity Ratio Analysis & Free Expert Stock Watchlists - earlytimes.in
Theriva Biologics (TOVX) asks holders to OK 16.18M warrant shares, $8.7M cash - Stock Titan
Have you been able to find a good deal on Theriva Biologics Inc’s shares? - uspostnews.com
Highs Report: Why institutional investors increase stakes in Theriva Biologics Inc. (SFY0) stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - moha.gov.vn
Why Theriva Biologics Inc. stock appeals to dividend investorsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - Улправда
Hedge Fund Moves: Is Theriva Biologics Inc. stock supported by strong fundamentals2025 Market Overview & Precise Entry and Exit Recommendations - Улправда
Is Theriva Biologics Inc. stock supported by strong fundamentals - Улправда
How risky is Theriva Biologics Inc. stock nowFed Meeting & Free Accurate Trade Setup Notifications - Улправда
Can Theriva Biologics Inc. stock deliver strong Q4 earningsJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - DonanımHaber
Is Theriva Biologics Inc. stock at risk of policy regulationJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - DonanımHaber
What analyst consensus implies for Theriva Biologics Inc. (SFY0) stockJuly 2025 Catalysts & Short-Term Swing Trade Alerts - Улправда
Can Theriva Biologics Inc. stock deliver sustainable ROEMarket Trend Report & Weekly Setup with ROI Potential - DonanımHaber
Is Theriva Biologics Inc. stock a fit for income portfoliosJuly 2025 Fed Impact & High Return Stock Watch Alerts - DonanımHaber
Can Theriva Biologics Inc. stock sustain free cash flow growthWeekly Trade Review & Community Verified Swing Trade Signals - Улправда
Why Theriva Biologics Inc. stock is favored by pension fundsJuly 2025 Highlights & Weekly High Return Forecasts - Улправда
Will Theriva Biologics Inc. (SFY0) stock draw ESG focused funds2025 Sector Review & Free Expert Approved Momentum Trade Ideas - Улправда
Why analysts recommend Theriva Biologics Inc. stock2025 EndofYear Setup & Fast Gain Stock Trading Tips - Улправда
Theriva Biologics to reschedule special stockholder meeting after lack of quorum - Investing.com Nigeria
Theriva Biologics Reschedules Special Stockholder Meeting - TipRanks
Theriva Biologics reschedules special stockholder meeting - MSN
Theriva Biologics (NYSE American: TOVX) to hold new vote on warrant share issuance - Stock Titan
US Market Recap: How Theriva Biologics Inc SFY0 stock reacts to stronger dollarQuarterly Growth Report & Fast Moving Trade Plans - moha.gov.vn
Earnings Risk: How Theriva Biologics Inc SFY0 stock responds to job market shiftsCPI Data & AI Powered Market Trend Analysis - moha.gov.vn
Why Theriva Biologics Inc. stock is a strong buy call2025 Analyst Calls & AI Driven Stock Reports - Newser
Can Theriva Biologics Inc. (SFY0) stock test all time highs2025 Market Overview & Verified Swing Trading Watchlists - Newser
Why Theriva Biologics Inc. stock gets analyst attention2025 Institutional Moves & Weekly Top Performers Watchlists - Newser
How Theriva Biologics Inc. (SFY0) stock reacts to Fed tightening2025 Market Overview & Smart Investment Allocation Insights - Newser
Will Theriva Biologics Inc. stock outperform foreign stocksTake Profit & Daily Profit Focused Stock Screening - Newser
Will Theriva Biologics Inc. stock maintain strong growthQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Can Theriva Biologics Inc. stock reach $200 price targetJuly 2025 Fed Impact & AI Optimized Trading Strategy Guides - Newser
Will Theriva Biologics Inc. stock beat value stocksMarket Movers & Growth Focused Stock Pick Reports - Newser
Theriva Biologics (NYSE: TOVX) files resale for 16,184,560 warrant shares - Stock Titan
Can Theriva Biologics Inc. stock deliver consistent EPS growthPortfolio Return Report & Low Drawdown Trading Techniques - Newser
Will Theriva Biologics Inc. stock top growth indexesTrade Exit Summary & Safe Entry Zone Identification - Newser
Will Theriva Biologics Inc. stock outperform benchmarks2025 Market Overview & Weekly High Return Opportunities - Newser
How Theriva Biologics Inc. stock reacts to monetary easingJuly 2025 Market Mood & AI Forecasted Stock Moves - Newser
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Cap:
|
Volume (24h):